Edition:
United States

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
15 Dec 2017
Change (% chg)

$-0.03 (-2.00%)
Prev Close
$1.25
Open
$1.25
Day's High
$1.25
Day's Low
$1.20
Volume
23,789
Avg. Vol
30,910
52-wk High
$4.75
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio
Tuesday, 28 Nov 2017 04:30pm EST 

Nov 28 (Reuters) - Titan Pharmaceuticals Inc ::TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING.TITAN PHARMACEUTICALS-‍PURSUANT TO AGREEMENT, CO WILL GRANT MOLTENI AN EXCLUSIVE RIGHT AND LICENSE TO COMMERCIALIZE PROBUPHINE IN EUROPEAN UNION​.TITAN PHARMACEUTICALS INC - ‍TITAN AND MOLTENI EXPECT TO ENTER INTO DEFINITIVE LICENSE AND DISTRIBUTION AGREEMENT DURING Q1 OF 2018​.  Full Article

Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - Titan Pharmaceuticals Inc ::TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE.TITAN PHARMACEUTICALS - ‍ENTERED BINDING TERM SHEET UNDER WHICH CO WILL GRANT MOLTENI EXCLUSIVE LICENSE TO COMMERCIALIZE PROBUPHINE IN EUROPEAN UNION​.TITAN PHARMACEUTICALS INC - ‍TITAN AND MOLTENI EXPECT TO ENTER INTO DEFINITIVE LICENSE AND DISTRIBUTION AGREEMENT DURING Q1 OF 2018​.TITAN PHARMACEUTICALS - TERM SHEET PROVIDES MOLTENI TO PAY CO UPFRONT, NON-REFUNDABLE LICENSE FEE OF EUR 2.0 MILLION UPON EXECUTION OF LICENSE DEAL​.  Full Article

Accepts Titan's Marketing Authorization Application For Probuphine®
Monday, 27 Nov 2017 07:00am EST 

Nov 27 (Reuters) - Titan Pharmaceuticals Inc ::EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®.TITAN PHARMACEUTICALS INC - ‍EUROPEAN MEDICINES AGENCY HAS ACCEPTED FOR REVIEW ITS MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE​.  Full Article

Titan Pharmaceuticals reports Q3 loss per share of $0.20
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Titan Pharmaceuticals Inc :Titan pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.20.‍Titan is evaluating potential funding options​.‍At Sept. 30, had cash and cash equivalents of about $11.7 million, which co believes is sufficient to fund planned operations through Aug 2018​.  Full Article

Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder
Thursday, 26 Oct 2017 06:32am EDT 

Oct 26 (Reuters) - Titan Pharmaceuticals Inc :Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​.  Full Article

Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment.Opiant Pharma - co, Titan will conduct feasibility assessment of a subcutaneous implant using titan's proprietary proneura sustained release technology.  Full Article

Titan Pharmaceuticals Q2 loss per share $0.16
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Titan Pharmaceuticals Inc :Titan Pharmaceuticals reports second quarter 2017 financial results.Q2 loss per share $0.16.  Full Article

Titan Pharmaceuticals reports Q1 loss per share $0.14
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Titan Pharmaceuticals Inc : :Titan pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.14.Titan Pharmaceuticals Inc - Titan is on track to submit an MAA to EMA in Q4 of 2017.Titan Pharmaceuticals Inc - at March 31, 2017 titan had cash and cash equivalents of approximately $10.9 million.Titan Pharmaceuticals Inc - company believes is sufficient to fund planned operations through Q2 of 2018.  Full Article

Titan Pharmaceuticals posts Q4 loss per share $0.11
Thursday, 16 Mar 2017 07:00am EDT 

Titan Pharmaceuticals Inc : Titan pharmaceuticals reports full year and fourth quarter 2016 financial results . Q4 loss per share $0.11 . At dec. 31, 2016, co had cash of approximately $14.0 million, compared with approximately $7.9 million at dec. 31, 2015 .Its working capital at Dec. 31, 2016 is sufficient to fund operations through Q1 of 2018.  Full Article

Titan Pharma receives FDA communication on ropinirole implant INDA
Monday, 27 Feb 2017 05:46pm EST 

Titan Pharmaceuticals Inc : Titan Pharmaceuticals receives FDA communication on ropinirole implant investigational new drug application . Titan Pharmaceuticals Inc - FDA has completed its initial review of ropinirole implant investigational new drug application . Titan Pharmaceuticals-FDA requested that co hold initiation of clinical study pending submission of requested information and agency's 30-day review . Titan Pharmaceuticals-FDA indicated it will require final release test data on ropinirole implant, applicator used to insert implant before clearing ind . Additionally, FDA is requesting that Titan identify a participating principal investigator for ropinirole study .Titan Pharmaceuticals - expects to have final test data on implant, applicator within next several weeks.  Full Article

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING